Extract

This randomized, double-blind, placebo-controlled, multi-center study will evaluate the safety and the effect of RO5093151 on intraocular pressure in patients with ocular hypertension or open angle glaucoma. Patients will be randomized to receive oral doses of RO5093151 or placebo twice daily. The anticipated time on study treatment is 7 days with the possibility to extend to 28 days.

Inclusion criteria

• Hypertension, Glaucoma, Open-Angle

Country

• Bulgaria
• Czech Republic
• Hungary
• United States

Links

• ictrp
• nct